Inverness Medical has presented the study published in Intensive Care Medicine, carried out in Vicenza, Italy. The study tested blood samples collected during admission to the ICU using the Triage NGAL Test, a product currently sold by Inverness Medical, outside of the US.
According to a new study published, a bedside blood test measured in critically ill patients being admitted to the intensive care unit can help to identify which patients are at risk for acute kidney injury (AKI).
Earlier this year, a small study conducted at the University Hospital of Clermont-Ferrand, France and published in the Journal of Critical Care found that a new bedside blood test for a blood biomarker called neutrophil gelatinase-associated lipocalin (NGAL) offered the promise of rapidly assessing if a critically ill patient is suffering from AKI.
The results from the Department of Nephrology at San Bortolo Hospital in Vicenza Italy have confirmed these findings in a larger study published in Intensive Care Medicine.
In this study of 301 patients, plasma NGAL measured with the Triage NGAL Test was a diagnostic marker for AKI development within the next 48 hours, and for renal replacement therapy use. Moreover, peak plasma NGAL concentrations increased with worsening AKI severity (R=0.554, p<0.001).
Claudio Ronco, professor of the San Bartolo Hospital in Vicenza, said: “We are living in an exciting era where it seems possible to diagnose AKI much earlier than before thanks to NGAL, a new promising biomarker of kidney damage. This may contribute to have a diagnosis in place, especially in the area of critically ill patients where an early detection of kidney insult may allow to stop harmful interventions or to install preventive /protective therapies that before were precluded or not indicated.”
